Wednesday, November 18, 2026

CalOptima in a Spotlight (2026) by Keith Torkelson MS, BS VTorkel

  



Contents

  • Requirements & Specifications
  • Stars Calculation – Satisfaction – Overall 15 Items (HSF)
  • 20260512 – My Care Plan – Collaborative Effort
  • Stars Ratings
  • One Care CMS Stars
  • Expectations of a Health Insurer
  • Satisfaction with Health Insurance Scale 27 Items (HSF)
  • Special Topic - Lab work
  • Corporate and Agency - Centered about CalOptima
  • FYI - Key Executive Officers
  • CalOptima Health Announces Retirement of Chief Executive Officer Michael Hunn
  • Impact of Clinic and Specialists on Insurers Ratings
  • In Another Life
  • Promotion – Gilbert Drugs
  • Plan Materials (OneCare)
  • Promotion - Sycamore Dental
  • Specialists not Seen
  • Promoting – DWD
  • Promoting - EOLCCA
  • Clinic Central City Community Health Center Survey (4 Pages)
  • Benefits – Satisfied – One Care Perks & Services
  • 2026 Benefit History Highlights
  • CMS Stars Scores
  • CalOptimas Story
  • Appendix - Contact Numbers Page - Member Services Department

Code

CO = CalOptima
HSF = High Scores are Favorable
LSF = Low Scores are Favorable
RT = Real Time
SW = Share (d) With


Stars Calculation – Satisfaction – Overall 15 Items (HSF)

Concentration on things in-scope of Imperial & CalOptima (CO)

Scored by Keith “Buster” Torkelson and ACA




Compare with National Committee for Quality Assurance’s (NCQA) 2023 = 4.0 Stars for Cal Optima

20260512 – My Care Plan – Collaborative Effort

 

  • &More (OTC) - PRN
  • Anxiety
  • Bi-polar
  • Cigarette Smoking – 7-8 per day
  • COPD
  • Falling risk improved
  • Harmony
  • Peace
  • Referrals EOL Planning
  • Rewards
  • RX Gap Free
  • Sleep
  • Walking vs. Gym

 


Stars Ratings

[Link breaks > Lost information]

ORANGE, Calif. (September 15, 2023)

CalOptima Health is pleased to announce its rating of 4 stars out of 5 stars in the National Committee for Quality Assurance’s (NCQA) Medicaid Health Plan Ratings 2023. This is the ninth year in a row that CalOptima Health is among the top plans in the state, representing sustained leadership in serving its Medi-Cal insured members. CalOptima Health provides health insurance to about 980,000 individuals, which represents nearly 1 in 3 Orange County residents.

 

Why are Stars in Healthcare important?

Medicare Star Ratings (1-5 stars) are vital because they provide a standardized, transparent way for consumers to compare the quality of Medicare Advantage and prescription drug plans. They drive higher quality care, reward top-performing plans with bonuses, improve patient experience, and help beneficiaries choose plans with better health outcomes.

Why doesn’t CalOptima have a CMS Stars Rating? [DITTO]

CalOptima Health does have high quality ratings, although they are primarily recognized through the National Committee for Quality Assurance (NCQA) for Medi-Cal rather than a standard 1–5 star rating on the Medicare.gov Plan Finder for all products. CalOptima Health received a 4-star rating in the NCQA Medicaid Health Plan Ratings 2023, marking the ninth consecutive year it was ranked among top plans in California.

Here is why there may be confusion regarding a CMS Stars Rating:

Medi-Cal Focus:

CalOptima is a County Organized Health System (COHS) primarily serving Medi-Cal members. While NCQA evaluates Medi-Cal plan quality based on clinical measures and member satisfaction, this is a different rating system than the annual 5-star rating CMS publishes for Medicare Advantage plans.

Medicare Product (OneCare):

For its Medicare product (OneCare), CMS Star Ratings are applicable. Information regarding 2025 Medicare Star Ratings for CalOptima Health OneCare is listed, indicating it is treated as a Medicare Advantage plan.

Performance Metrics:

NCQA ratings are based on 45 clinical measures, including preventive services and treatment, rather than the specific, annually updated CMS stars formula for Medicare plans. In summary, CalOptima is rated and operates as a high-performing plan (4 stars, NCQA), but its primary focus is on Medi-Cal rather than Medicare Advantage.

 

One Care CMS Stars

https://cop-p-001.sitecorecontenthub.cloud/api/public/content/e3c1236b9c9145b88c8644756304b972?v=069aba85



Expectations of a Health Insurer

Whether you are evaluating a new plan or holding your current provider accountable, you should expect transparent pricing, broad provider access, reliable claims processing, and responsive support from a health insurer.

Coverage & Network Access

Broad Provider Network.

Your plan should include a wide range of local primary care doctors, specialists, and major hospitals in-network to prevent surprise out-of-network bills.

Clear Specialist & Referral Rules.

You should know upfront whether you need a primary care referral to see a specialist or if you have direct access.

Comprehensive Drug Formulary.

Your regular prescriptions should be covered under an easy-to-understand tiered formulary, with clear rules around step therapy or prior authorizations.

Free Preventive Care. Routine annual checkups, vaccinations, and standard health screenings should be covered at no extra out-of-pocket cost.

Financial Transparency & Reliability

Predictable Cost-Sharing.

The insurer must clearly state your monthly premium, annual deductible, copayments, coinsurance, and out-of-pocket maximum before you enroll.

Prompt & Fair Claims Processing.

Valid medical claims should be paid accurately and on time without unjustified delays or excessive administrative hurdles.

Financial Stability.

The company should have strong financial ratings and a proven track record so you can trust they will reliably cover major medical emergencies.

Clear Explanation of Benefits (EOB).

After every medical visit, you should receive an easy-to-read breakdown showing what the provider billed, what the insurer paid, and what you owe.

Customer Service & Digital Experience

Responsive Support.

You should have easy access to knowledgeable representatives who can resolve billing errors, coverage questions, and appeals quickly.

User-Friendly Digital Tools.

The insurer should provide an up-to-date online portal or mobile app to search for in-network doctors, view digital ID cards, track deductible progress, and estimate procedure costs.

Smooth Care Coordination.

When dealing with chronic conditions or complex treatments, the insurer should coordinate smoothly with your healthcare providers rather than creating communication bottlenecks.

Straightforward Appeals Process.

If a treatment or medication is denied, the insurer must provide a clear reason and a transparent process to appeal the decision.


 

Satisfaction with Health Insurance Scale 27 Items (HSF)

Scored by and for Keith “Buster” Torkelson, MS

##

Aspect

2026
1118
W-RT
SW-Solo

01

24/7 customer service

1.00

02

Affordable

1.00

03

Approval of specialists

1.00

04

Awesome customer service

1.00

05

Behavioral Health friendly

1.00

06

Better Outcomes

0.95

07

Broad provider network

1.00

08

Clear explanation of benefits

1.00

09

Comprehensive drug formulary

1.00

10

Comprehensive medical coverage

1.00

11

Easy access to urgent care

0.75

12

Effective care coordination

0.75

13

Fair claims processing

1.00

14

Favorable cost-sharing

1.00

15

Favorable digital experience

NA

16

Favorable prescription drug coverage

1.00

17

Financially Stable

UKN

18

Free preventive care

1.00

19

No surprise bills

1.00

20

OTC Benefit

1.00

21

Predictable co-pays

1.00

22

Responsive support

0.95

23

Smooth care coordination

0.75

24

Stellar supportive benefits

1.00

25

Transparency

0.75

26

User friendly appeals process

1.00

27

User friendly digital tools

NA

 

CALC

=22.9/24

 

Satisfaction with Health Insurance Score 27 Items (HSF) =

95.4%

 

Star Equivalents =

4.8

 

Duration 2024-2026

We have been insured by Cal Optima since 2024.


Health Related Engagements = HREs

We had a busy year seeing our PCPs and specialists.  We finally didn’t work our way free of appointments until November of 2026.  For us we consider 2026 a success.  Close yet no hospitalizations.

 

Perspectives

“I need perspective”

  • Insurer
  • Clinical/Clerical
  • Consumer
  • PCP
  • Specialists


Legacy Insurance > In House > Metadata >
Imperial_2023_Medicare_Experience_Survey_MES_23101801_Results
CMS_Medicare_Satisfaction_Survey_18093003_Notes V2023
Includes 2023 Medicare Experience Survey (MES) – Topics & Scoring
 

Special Topic - Lab work

We prefer Quest over Labcorp. For one we have an account set up with Quest.  Two Labcorp has billed us whereas Quest is no out-of-pocket.  Quest has served us since 2012 and before.  We are satisfied with Quest Diagnostics.  Our lab expenses have dropped substantially since the registry does not require CBCs.  We still have routine CBCs with: Our annual physical, annual wellness visit and for any specialists that order them.


Corporate and Agency - Centered about CalOptima




FYI - Key Executive Officers

https://www.caloptima.org/en/about-us/board-and-leadership/executive-management

 

  • Michael Hunn – Chief Executive Officer (Retiring)
  • Veronica Carpenter – Chief Administrative Officer
  • Nancy Huang – Chief Financial Officer
  • Steve Eckberg – Chief Human Resources Officer
  • Kathleen Linder – Chief Information Officer
  • Richard Lopez Jr. (Interim) & Zeinab Dabbah (Deputy) – Medical Officers
  • Michaell Silva Rose – Chief Health Equity Officer
  • John Tanner – Chief Compliance Officer

 

CalOptima Health Announces Retirement of Chief Executive Officer Michael Hunn

Published: January 22, 2026

[WE KEPT THIS BECAUSE IT MAY DISAPPEAR-IT IS A REPRINT]

https://www.caloptima.org/en/about-us/press-releases/caloptima-health-announces-retirement-of-chief-executive-officer-michael-hunn

Jan 22, 2026 — Hunn joined CalOptima Health as interim CEO in November 2021, bringing decades of health care experience to the role, and was named CEO in 2022

ORANGE, Calif. (January 22, 2026) — CalOptima Health Chief Executive Officer Michael Hunn, an innovative leader who championed expanded Medi-Cal services and increased community investments in housing as a foundation for health, will retire on December 31, 2026. As the health plan’s leader for the past five years, Hunn has been deeply committed to serving low-income and vulnerable populations and supporting the health care safety net. Hunn’s focus on putting members at the center of the organization contributed to CalOptima Health’s growth, increased employee and provider engagement, and brought positive recognition among public health plans.

During Hunn’s tenure, CalOptima Health established itself as a national leader in promoting equitable health care for low-income members and as a catalyst for community transformation. He restored community trust in CalOptima Health by implementing strong reform and compliance measures. Hunn’s accomplishments include creating Street Medicine programs in four cities across Orange County, establishing a department dedicated to implementing CalAIM benefits to address social determinants of health, awarding more than $306 million in community grants, expanding access to care by adding Providence as a 10th health network, implementing workforce development grants to reduce provider shortages, overseeing expanded communications, marketing and community outreach efforts to raise awareness, and leading a successful initiative that allows CalOptima Health to pursue launching a Covered California plan in the future.

“I am proud of everything we have achieved at CalOptima Health over the past five years, and I will remain fully committed and focused through the end of the year,” Hunn said. “We have reinvigorated CalOptima Health and reestablished our plan as a trusted community partner that serves members with dignity and respect. Together with CalOptima Health’s Board of Directors, executive leaders, staff and numerous Orange County leaders, we have made a difference in the community and fulfilled the mission to serve members. We just celebrated our 30-year anniversary, and our commitment to quality care for those most in need has never been stronger.”

Hunn joined CalOptima Health as interim CEO in November 2021, bringing decades of health care experience to the role, and was named CEO in 2022. Under his leadership, CalOptima Health embraced opportunities for positive reform and established a culture of continuous improvement. He oversaw the successful implementation of all recommendations from an exhaustive state audit, investing reserve funds to expand health care access and services, funding education and workforce grants, and enacting multiple rate increases that benefited safety net providers and hospitals. CalOptima Health consistently spends more than 95% of its budget on health care services and less than 4.5% on overhead expenses, which is among the lowest overhead rates for any health plan in California.

“We are grateful for Michael’s visionary leadership of CalOptima Health and his meaningful collaboration with his colleagues and the broad network of partners that make our organization exceptional,” said Supervisor Vicente Sarmiento, Chair of CalOptima Health’s Board of Directors. “Michael’s innovative thinking, steadfast pursuit of strategic initiatives for our members, and careful stewardship of the organization’s resources have prepared us to confront an ever-changing and complex environment for health care.”

Press Release: CalOptima Health Announces Retirement of Chief Executive Officer Michael Hunn

As CEO, Michael Hunn is routinely at community events across Orange County to better understand who CalOptima Health serves. Here, he attends a groundbreaking ceremony for a new housing development in Costa Mesa and meets with CalOptima Health members.




About CalOptima Health

A county organized health system, CalOptima Health provides quality health care coverage for low-income children, adults, seniors and people with disabilities in Orange County, California. CalOptima Health’s mission is to serve member health with excellence and dignity, respecting the value and needs of each person. CalOptima Health serves more than 877,000 members with a network of more than 9,200 primary care doctors and specialists and 42 acute and rehab hospitals. Promotion: Visit www.caloptima.org.

Impact of Clinic and Specialists on Insurers Ratings

Clinics and specialists shape insurer ratings in two main ways: through measured clinical quality and care coordination, and through patient trust and perceived plan value.

Clinical Quality & Network Structure

Care coordination and integration:

Provider-sponsored health plans—owned by or affiliated with health systems and clinics—have been linked to higher overall quality ratings in ACA marketplaces, including stronger clinical quality and enrollee experience.

Network control:

Insurers with looser network oversight, such as many PPO arrangements, can see lower scores on certain guideline-concordant care metrics compared to plans with tighter care management.

Coding and exclusions:

In value-based arrangements, clinics and specialists help ensure accurate quality scores by using proper ICD-10 exclusion codes when patients are ineligible for specific measures due to advanced illness, frailty, or clinical history.

Patient Trust & Friction Points

Primary care and specialist experience:

Trust in primary care physicians and positive specialist visits—including smooth primary-to-specialist coordination—can reinforce how enrollees view their health plan. Poor provider experiences or frequent provider changes can erode that trust.

Prior authorization and denials:

Friction over prior authorizations, step therapy, and claim denials creates delays and administrative strain across clinics and specialists, which affects how patients and doctors view insurer follow-through. Research from the American Medical Association highlights ongoing physician skepticism toward insurer prior authorization commitments, while a scoping review in PMC notes how provider quality and trust link to insurer reputation. Additional findings on provider-sponsored plans appear in Health Affairs Scholar.

 

Insurer Immunity

>Unless the insurer and clinic is co-located, insurers such as Cal Optima have little or no control over how the clinics and specialists offices are run.  Therefore, with respect to rating the insurers should be immune to the impact of how the clinics and specialists perform.

Note: Cal Optima administrative staff
Single Point Contact with Corporate – Amy & Alexis
 
Aside - Personalized Letters from Corporate
Example – Constance Snider with Brand New Day
09_BND_Report_15062801_CJS V2023 Imperial

 

In Another Life

>In another life we would share this report with CalOptima.  We hope they find it online one day or another. We used to give reports to our insurer, clinic staff and specialists.  This is our Christmas Report Card (CRC) for 2026.


 

This is subject to change
Who is the CEO of CalOptima?
[LINK BROKE and REMOVED]
Michael Hunn - Chief Executive Officer

As Chief Executive Officer, Michael Hunn is responsible for the mission of CalOptima, its systems and structures as well as overall strategic business, financial and community planning.

 

Michael Hunn – CalOptima




Provider Newsletter
[LINK BROKE AND REMOVED]
 
20260414-SU-Who is the CEO of CalOptima?
CalOptima Health Announces Retirement of Chief Executive Officer Michael Hunn
Published: January 22, 2026
[LINK BROKE AND RETAINED FOR METADATA]
https://www.caloptima.org/en/about-us/press-releases/caloptima-health-announces-retirement-of-chief-executive-officer-michael-hunn

 

Aside - Ancillary Aspects (2026)




Promotion – Gilbert Drugs

https://www.gilbertdrugspharmacy.com/

Located in: Hahn's Plaza

Address: 9240 W Garden Grove Blvd #20, Garden Grove, CA 92844

Phone: (714) 638-8230

Pharmacy Specializing in Patients, Assisted Living Facilities (ARF), Residential Care Facilities for the Elderly (RCFE), & Hospices in Orange County, Los Angeles, & San Bernardino Areas

 

Plan Materials (OneCare)

  • Summary of Benefits (2026)
  • Annual Notice of Change (2026)
  • Urgent Care
  • OTC &more Catalog (For 2026 Received 12-17-2025)

 

Promotion - Sycamore Dental
https://www.sycamoredentalgroup.com/
Call: 714-995-6000
6850 Lincoln Ave.
Buena Park, CA 90620
Full Service

Does full spectrum of services: General dental, endodontics, oral surgery and more.  Everything was covered including dentures for 2026.  Dental implants are not covered.



Specialists not Seen

  • Audiologist
  • Chiropractor
  • Palliative Care
  • Podiatrist
  • Social Worker
  • Surgeon
  • Thanatologist

 

Associated Documents > In House > Metadata >
11_HRE_Physical_18082501_Assessment V2023


Promoting – DWD

https://deathwithdignity.org/

The Death with Dignity National Center is a 501(c)(3) nonpartisan nonprofit organization based in Portland, Oregon, that focuses on education, public information, and legal defense around medical aid in dying (also referred to as "death with dignity") laws modeled on the Oregon Death with Dignity Act.

Key Details

Legal Status: 501(c)(3) nonprofit (Tax ID: 93-1162366), formed in December 1994 (originally as The Oregon Death with Dignity Legal Defense and Education Center).

Headquarters:

Portland, Oregon.

Affiliated Entity:

Works alongside the Death with Dignity Political Fund, a separate 501(c)(4) organization that handles lobbying, drafting legislation, and political advocacy.

Mission & Activities:

Helps protect and defend existing laws, educates the public, healthcare professionals, lawmakers, and students, and advocates for expanding end-of-life options for terminally ill adults.

Official Resources

Learn about the organization's work and policy efforts on the Death With Dignity website.

Review background history and legal milestones on the Death with Dignity National Center page.


Promoting - EOLCCA

https://endoflifechoicesca.org/

Knowledge. Support. Compassion.​

Navigating end-of-life decisions is deeply personal. Our mission is to empower Californians with accurate information, compassionate counseling, and unwavering respect for individual choice during life’s most difficult times


Clinic Central City Community Health Center Survey (4 Pages)
Clinician and Group Experience Survey
PCP, Psychiatrist & Lab











Aside – From > In House > Metadata >
09_BND_Omega_22100601_Notes


Benefits – Satisfied – One Care Perks & Services
Usual and Customary
HSF = High Scores are Favorable





CMS Stars Scores
 
Aside - FYI - Imperial Health Plan of California Termination Notice – CMS
https://www.cms.gov/files/document/imperialtermination02222023.pdf

[4 Pages] CMS has determined that Imperial has substantially failed to carry out its contract with CMS by failing to achieve a Part D summary Star Rating of at least three stars in the past three most recent Star Rating periods for contract H2793. H2793 is a MA-PD contract that has been in operation since January 1, 2019. Feb 22, 2023

 

Imperial Health Plan - Dynamic
20230328-TU: Star Ratings - 2023
 
Source(s)
CMS Stars – 5 Stars is Superior





FYI

2019_STAR-Ratings_EN CMS BND.pdf

 

CalOptimas Story

CalOptima Health is Orange County’s largest public health insurance provider, covering nearly one in three residents, including over 300,000 children. Founded in 1993, it manages Medi-Cal benefits to improve care access, offering specialized services, street medicine, and community-based support, while operating as a vital safety net.

Key Aspects of the CalOptima Story:

Mission & Focus:

CalOptima serves member health with excellence and dignity, focusing on removing barriers to care and improving health outcomes for low-income residents. Origin: It was established in 1993 by the Orange County Board of Supervisors to address a crisis where Medi-Cal beneficiaries were using emergency rooms for primary care.

Expansion & Impact

Serving over 300,000 children and nearly one in three Orange County residents, it has grown significantly to become the main public insurer in the area, often partnering on initiatives like the street medicine program for the homeless.

Community Care & Support:

CalOptima supports member needs through specialized programs such as housing navigation, as seen in the story of member Ruth, who overcame housing insecurity with their assistance.

Recent Challenges:

A July 2025 audit reported by the Voice of OC suggested the agency had built up large surpluses, while other reports have noted challenges with enrollment decline due to complex, changing regulations and community fears. CalOptima continues to focus on its mission to provide accessible healthcare, expanding its services through initiatives like the CalAIM program to provide better care coordination, says this article.

 

Associated Documents > In House > Metadata >
Imperial_Assessment_Derived_from_Online_Materials_23080301_Notes
06_NCQA_UEDP_17030701_Notes V2023

  

Appendix - Contact Numbers Page - Member Services Department
Promoting CalOptima
https://www.caloptima.org/en/about-us
https://member.caloptima.org/#/user/login
 
CalOptima Important Numbers

CalOptima Health serves Orange County, California, providing Medi-Cal, OneCare (Medicare Advantage), and PACE plans. Members should use the number on their ID card for provider info.

 

Key CalOptima Health Numbers:

  • Medi-Cal Customer Service: 1-888-587-8088
  • OneCare Customer Service: 1-877-412-2734
  • PACE Information: 1-877-412-2734
  • TDD/TTY: 711
  • Transportation (Non-Emergency): 1-888-587-8088

 

Other Important Contacts:

  • Emergency Care: Call 9-1-1 or visit the nearest emergency room.
  • Member Health Rewards: 1-800-306-6476 (For checking eligibility and rewards).
  • Behavioral Health (Medi-Cal): 1-800-723-3596.

Provider Information: Check your ID card or call the Find a Doctor Search Tool on the CalOptima website.

 

Note: For the most updated information, always refer to the number listed on the back of your Member ID card.



Sunday, November 15, 2026

Psychotropic Trials on Consumers of Behavioral Health Services by Keith Torkelson MS, BS VTorkel

  


Contents

  • Requirements and Specifications
  • Results Up Front
  • Results Up Front – Master Medications List
  • When a doctor tries you on a new medication is it an experiment?
  • Experimentation on Human Subjects
  • Clozapine Algorithm
  • Fleshing Issues by Medication
  • E.H.R. Experiment – Increase in Error Rate (Circa 2026)
  • Chemically validated diagnoses for mental illness
  • Typical Antipsychotics
  • Atypical Antipsychotics
  • More - How is it that Risperadone and Invega were ineffective for me?
  • Fleshing Issues by People (MDs & NPs)
  • Brain Games – Reversing or Slowing the Effects of Dementia
  • Integrated Circuits to Treat Mental Illness
  • Therapeutic changes in brain circuitry and chemistry
  • Evolution of ECT
  • What is a Chemical Lobotomy?






Results Up Front – Master Medications List – Part I of II

Not in Chronological Order




Master Medications List – Part II of II

Not in Chronological Order




When a doctor tries you on a new medication is it an experiment?

No, giving you a new medication is generally not an experiment.

Why It Is Not an Experiment

Extensive Testing First:

Before a medication is approved by agencies like the U.S. Food and Drug Administration (FDA), it undergoes years of laboratory research and Clinical Trials (Phase I–III) involving thousands of patients to prove it is safe and effective.

Tailored Treatment:

When your doctor prescribes a new medication, they rely on clinical guidelines, medical training, and your specific health history to find the best option for your condition—not to test an unknown theory on you.

Individual Response:

Every person's body reacts differently to pharmaceuticals. Adjusting a dose or switching to a different drug is a process of individualized fine-tuning, rather than scientific experimentation.

When Medication Is Experimental

A medication is considered experimental only under specific circumstances:

Clinical Trials:

You are explicitly enrolled in a structured Clinical Trials Research Study designed to answer a scientific research question.

Investigational Drugs:

You are taking a drug that has not yet received regulatory approval and is still being tested for safety or efficacy, often accessed through specialized trials or expanded access programs.

Off-Label Use:

A doctor prescribes an already-approved drug for a condition or age group it wasn't originally studied for. While common and legal, this relies on clinical experience rather than primary trial data for that specific use.

 

Experimentation on Human Subjects

Experiments on human subjects involve systematic scientific investigations—either interventional or observational—designed to collect data for medical or social science research.

Core Ethical Principles

Modern human subject research is guided by strict legal and ethical frameworks to prevent abuse and protect participants:

Voluntary Informed Consent:

Subjects must fully understand the nature, risks, and benefits of a study and agree to participate of their own free will.

Right to Withdraw:

Participants can leave a study at any time without facing penalties or loss of benefits.

Protection from Harm:

Researchers must minimize physical, psychological, or social risks.

Institutional Oversight:

Most regulated research requires approval from an Institutional Review Board (IRB) or ethics committee before it can begin.

Key Historical Milestones

Global and national guidelines were shaped largely in response to historical violations:

Nuremberg Code (1947):

Formulated after World War II in response to Nazi medical atrocities; established the absolute necessity of voluntary consent.

Declaration of Helsinki (1964):

Developed by the World Medical Association as a cornerstone guide for ethical medical research involving human subjects.

Belmont Report (1978) & Common Rule (1991):

Set the foundation for ethical research regulations in the United States, emphasizing respect for persons, beneficence, and justice.

Notable Examples of Unethical Experiments

History includes many instances where ethical principles were severely violated, often targeting prisoners, soldiers, or marginalized populations without consent:

Nazi Human Experimentation & Unit 731:

Brutal medical torture, hypothermia studies, and biological warfare tests conducted during World War II.

Tuskegee Syphilis Study:

A multi-decade U.S. Public Health Service study that withheld treatment from Black men with syphilis without their informed consent.

Project MKUltra:

Clandestine U.S. CIA experiments involving mind-altering substances like LSD and psychological interrogation techniques.

Psychological Studies:

Famous social experiments like the Stanford Prison Experiment and the Milgram obedience experiments raised serious questions about psychological harm and participant distress.


Clozapine Algorithm

We should have been tried on CloZAPine after 3-4 failures on anti-psychotics

We were a candidate in the early 1990s yet did not get on it until 2006



Fleshing Issues by Medication

Common issues and side effects caused by medicines fall into several main categories, ranging from routine reactions to severe medical risks.

Common Physical and Digestive Side Effects

Digestive discomfort:

Nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and iron supplements can cause nausea, diarrhea, constipation, gastritis, or stomach ulcers.

Esophageal irritation:

Pills like aspirin, doxycycline, or vitamin C can stick in the throat and cause local ulcers or bleeding if swallowed without enough water.

Drowsiness and dizziness:

Antihistamines, antidepressants, blood pressure medications, and sleep aids frequently cause fatigue, brain fog, or lightheadedness.

Balance and fall risks:

Polypharmacy (taking multiple drugs at once) and high-risk medications like sedatives or muscle relaxants increase the chance of falls, especially in older adults.

Drug Interactions

Pharmacokinetic changes:

One drug can alter how another is processed by the liver or kidneys (for example, grapefruit juice interacts with statins to raise drug levels in the blood).

Additive or dangerous effects:

Combining blood thinners with NSAIDs escalates bleeding risks, while mixing St. John's wort or herbal supplements with antidepressants can trigger life-threatening serotonin toxicity.

Severe Allergic and Systemic Reactions

Severe skin and immune reactions:

Rare but life-threatening responses include Anaphylaxis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS reaction.

Symptom masking:

Using over-the-counter or temporary symptom-relief drugs without identifying the root cause can allow underlying diseases to progress dangerously.

Supply Chain and Manufacturing Issues

Generic drug quality and shortages:

A large portion of generic drug manufacturing occurs overseas, leading to occasional oversight challenges, contamination risks, and shortages of vital treatments in the United States.


E.H.R. Experiment – Increase in Error Rate (Circa 2026)

Studies show that Electronic Health Record (EHR) error rates vary widely—ranging from 15% to over 50% depending on task complexity, vendor design, and workflow delays.

Key Findings on EHR Error Rates

Operating Room Documentation:

A recent PMC study found an overall documentation error rate of 17.01%, surging from 1.30% with no delay to 38.43% for documentation delays exceeding 20 minutes 0.6.1.

Medication Errors:

Research from University of Utah Health revealed that EHR systems fail to detect up to 33% (one in three) of potentially harmful medication errors and drug interactions.

Task Variability:

A JAMIA study tracking emergency medicine ordering scenarios across Epic and Cerner systems found error rates reaching up to 50%, with an eightfold difference in required mouse clicks.

Patient-Reported Mistakes:

In a JAMA Network Open study, 1 in 5 patients who read their visit notes reported finding a mistake, with 40% perceiving the error as serious.

Main Causes of Increased Error Rates

Documentation Delays:

Rushing to catch up on delayed charting drastically spikes mistakes during high-intensity procedures.

Information Overload & Alert Fatigue:

Excessive notifications, poor interface design, and "note bloat" increase cognitive burden on clinicians.

Local Customization:

Hospitals often modify software and disable decision-support alerts independently, while federal regulations typically inspect only baseline factory software.

Copy-Paste Culture:

Reusing old text propagates outdated or inaccurate clinical information across charts.


Chemically validated diagnoses for mental illness

There are no chemically validated (biomarker-based) diagnostic tests used to confirm mental illnesses.

Clinical Assessment Only:

Psychiatric diagnoses—such as Major Depressive Disorder, Schizophrenia, Bipolar Disorder, or Anxiety—are made through clinical interviews, mental state evaluations, and standardized criteria like the DSM-5 rather than blood, urine, or brain-chemistry assays.

Excluding Physical Causes:

Lab tests (such as blood or thyroid panels, drug screens, or imaging) are ordered strictly to rule out non-psychiatric medical issues (like nutritional deficiencies, neurological tumors, or autoimmune conditions such as lupus) that can mimic psychiatric symptoms.

The "Chemical Imbalance" Myth:

The popular idea that mental health disorders are diagnosed or caused by a simple, measurable chemical imbalance in the brain is an oversimplification. While neurotransmitters, inflammation markers, and metabolomics are active areas of research, psychiatry currently relies on a bio-psycho-social model rather than objective chemical tests.



(*) Absolutely miserable medications.  Complicated anxiety and sleep issues.  Severe adverse reactions including Tardive Dyskinesia and Muscle Rigidity.



Other Medications

Risperadone (Risperdal) was ineffective for us.  Invega monthly injection was ineffective for us on two different occasions.  It makes sense that Invega would not be effective. Invega itself is not a metabolite; Invega (brand name for paliperidone) is already the active form and is the major active metabolite of the older antipsychotic medication risperidone (Risperdal).

 

More - How is it that Risperadone and Invega were ineffective for me?

Risperidone and Invega (paliperidone) are chemically almost identical, meaning that if one does not work for your body, the other is also very likely to be ineffective. When your body processes risperidone, it breaks it down into paliperidone, which is the exact active ingredient in Invega. Because both drugs act on the exact same brain pathways, they share the same core mechanism. Several biological and clinical factors can explain why neither medication worked for you.

Shared Pharmacology

The Active Metabolite Link.

Paliperidone is the primary active metabolite of risperidone. Taking Invega essentially skips the liver processing step required by risperidone, delivering the same active compound directly to your system.

Identical Receptor Targets.

Both medications work primarily by blocking specific dopamine (D2) and serotonin (5-HT2A) receptors in the brain. If your specific symptoms are not driven by this exact receptor pathway, neither medication will provide relief.

Individual & Clinical Factors

Genetic Variations in Brain Receptors.

Every person has unique variations in their dopamine and serotonin receptors. Your specific receptor makeup may simply not respond well to how these two drugs bind to them.

Diagnosis and Symptom Mismatch.

While both medications treat conditions like schizophrenia, they do not target every symptom type equally. For instance, they are generally less effective for depressive episodes or negative symptoms like low motivation and emotional blunting.

Duration Limits.

Antipsychotic medications often take several weeks to show their full effect. If treatment was stopped early or adjusted before reaching a stable regimen, the medication may not have had an adequate period to work.

Treatment Resistance.

Some individuals have conditions that do not respond to standard first-line dopamine blockers. In these cases, a completely different class of medication—such as cloZAPine or newer agents that target different brain chemicals—is often needed.

What to Discuss With Your Prescriber

Trying a Different Chemical Class.

Since both of these drugs rely on the same compound, ask your doctor about switching to an antipsychotic with a different chemical structure and receptor profile.

Reviewing Your Trial History.

Share the details of your previous regimens and how long you took each medication so your doctor can evaluate if you completed a full clinical trial.


Fleshing Issues by People (MDs & NPs)

Scored by and for Keith “Buster” Torkelson, MS, BS




These values have been updated since publishing a report card in previous studies.

(*) Dr. Dobos had bi-weekly medication management groups which was the most efficient manner to handle a caseload that we ever experienced.  Unfortunately we went to the hospital on his watch.

(**) These scores will vary between papers and are subject to change.

 

Brain Games – Reversing or Slowing the Effects of Dementia

Brain games and cognitive exercises target specific mental skills like memory, attention, problem-solving, and speed.

 

Popular Online Platforms & Apps

 

Lumosity:

Features over 40 research-inspired games targeting memory, speed, attention, flexibility, and problem-solving.

Games for the Brain:

Offers classic browser-based logic and puzzle games like Sudoku, Chess, Checkers, Reversi, and Mahjongg.

Mind Games:

Provides a free catalog of daily word searches, nonograms, Sudoku, crosswords, and memory games.

Wordle & Variations:

Daily word puzzles like the official NYT Wordle or community-favored variations (Quordle, Octordle) help with vocabulary and pattern recognition.

 

Classic & Real-World Brain Games

 

Number Puzzles:

Sudoku and number sums build logical thinking and concentration.

Word & Language Games:

Crosswords, Scrabble, Boggle, and Taboo strengthen verbal fluency and crystallized intelligence.

Strategy & Board Games:

Chess, Checkers, Bridge, Uno, and Monopoly challenge executive function, working memory, and real-time problem-solving.

Visuospatial Puzzles:

Jigsaw puzzles, find-the-difference sheets, and mazes help protect visuospatial functioning as you age.


Integrated Circuits to Treat Mental Illness

Modern psychiatry increasingly views mental illness—such as treatment-resistant depression and obsessive-compulsive disorder (OCD)—not merely as a chemical imbalance, but as a disorder of brain circuits. Integrated circuits, microchips, and implantable electronic devices are at the forefront of a shift toward precision neuromodulation.

How Integrated Circuits and Implants Work in Psychiatry

Deep Brain Stimulation (DBS):

Involves surgically implanting miniature electrodes or pacemaker-like devices directly into specific brain regions (such as the subgenual anterior cingulate cortex). These integrated systems deliver controlled electrical pulses to modulate and "rewire" dysfunctional neural networks.

Closed-Loop Systems:

Newer implantable and wearable technologies are designed to monitor real-time brain activity and deliver stimulation only when specific biomarker patterns or abnormal circuit activity are detected.

Targeting Resistant Conditions:

These hardware approaches are primarily studied and deployed for patients with severe, treatment-resistant major depressive disorder (TRD) or debilitating OCD who have not responded to psychotherapy or multiple medications.

Non-Invasive Alternative Circuit Therapies

For patients who do not require or want surgical implants, circuit-level modulation is also achieved via non-invasive tools:

Transcranial Magnetic Stimulation (TMS):

Uses external electromagnetic coils placed on the scalp to stimulate mood-regulating brain regions like the dorsolateral prefrontal cortex without anesthesia or surgery.

Electroconvulsive Therapy (ECT):

A well-established clinical therapy that uses regulated electrical currents under anesthesia to induce therapeutic changes in brain circuitry and chemistry for severe episodes.

 


Therapeutic changes in brain circuitry and chemistry

Therapeutic interventions—including psychotherapy, pharmacotherapy, and neuromodulation—induce measurable structural and chemical adaptations in the brain through neuroplasticity.

Changes in Brain Circuitry (Structure & Activity)

Prefrontal Cortex (PFC):

Talk therapy and cognitive behavioral approaches strengthen top-down emotional regulation by increasing functional activity and gray matter volume in executive control regions.

Amygdala and Limbic System:

Overactive alarm centers that drive fear, anxiety, and hyper-reactivity show reduced baseline volume and decreased hyper-reactivity following successful treatment.

Synaptic Remodeling:

Interventions promote the growth of new dendritic spines and prune outdated or stress-induced connections, allowing neural circuits to reorganize.

Targeted Circuit Stimulation:

Advanced approaches like Vagus Nerve Stimulation or deep-brain stimulation directly target specific white-matter pathways (such as the subcallosal cingulate) to reset malfunctioning loops in treatment-resistant conditions.

Changes in Brain Chemistry (Neurotransmitters & HPA Axis)

Serotonin and Dopamine:

Therapeutic modalities elevate availability and receptor sensitivity for key mood-stabilizing and reward-regulating neurotransmitters.

GABA and Glutamate:

Treatments enhance inhibitory neurotransmission via GABA while dialing down excessive excitatory glutamate and norepinephrine signaling.

BDNF (Brain-Derived Neurotrophic Factor):

Therapy and lifestyle interventions trigger BDNF release, which supports the survival of existing neurons and encourages the growth of new synapses.

Stress Hormone Regulation:

Modulating the hypothalamic-pituitary-adrenal (HPA) axis lowers chronic cortisol output, protecting the hippocampus from stress-induced volume loss.

 

Would you like to explore how a specific intervention (such as Cognitive Behavioral Therapy, antidepressants, or mindfulness) affects a particular mental health condition?

 
Evolution of ECT

Electroconvulsive therapy (ECT) has evolved from a crude, unanesthetized chemical and electrical intervention into a highly regulated, safe, and precise neuromodulation procedure.

Key Stages of Evolution

Pre-ECT Chemical Convulsive Era (1930s): The practice grew out of early theories that induced seizures could alter mental illness. Ladislas J. Meduna used intramuscular camphor and later Metrazol (cardiazol) to chemically induce seizures in patients with schizophrenia, though it caused severe pre-seizure panic and high physical risk.

Invention of Electrical ECT (1938): Italian psychiatrists Ugo Cerletti and Lucio Bini replaced chemical agents with controlled electrical currents delivered to the scalp, performing the first human ECT treatment in Rome.

The "Unmodified" Era (1938–1950s):

Early ECT was administered "unmodified"—meaning without anesthesia or muscle relaxants. High-voltage alternating currents (AC) induced violent motor convulsions that occasionally led to bone fractures, dental injuries, and severe post-procedure confusion.

Introduction of Anesthesia and Muscle Relaxants (1940s–1952):

Wladimir T. Liberson (1944) shortened stimulus durations, reducing cognitive blunting.

General anesthesia and barbiturates were introduced for patient comfort.

Paralytic muscle relaxants—initially curare and later replaced by succinylcholine (1952)—eliminated violent physical muscle contractions while preserving the therapeutic brain seizure ("modified ECT").

Refinement of Electrical Waveforms and Placement (1970s–Present):

Brief-pulse and ultrabrief-pulse stimuli replaced traditional sine waves, drastically cutting down memory impairment and cognitive side effects.

Unilateral ECT (applying electrodes to only one hemisphere) was adopted alongside traditional bilateral placement to further protect memory function.

Modern Status:

Today, ECT is recognized as a vital, fast-acting treatment for severe, treatment-resistant depression, acute mania, catatonia, and psychotic depression, backed by safety standards and continuous innovations like magnetic seizure therapy.

 


What is a Chemical Lobotomy?

A chemical lobotomy is a non-medical, descriptive term used to describe the heavy sedation and emotional flattening caused by certain powerful psychiatric or sedative medications—most historically antipsychotics like chlorpromazine (Thorazine).

Origins and History

The Rise of Antipsychotics:

In the early 1950s, the introduction of early antipsychotic drugs like chlorpromazine revolutionized psychiatric care. Because these drugs rapidly calmed, quieted, and sedated agitated or psychotic patients without physical surgery, observers and historians dubbed them a "chemical lobotomy".

Replacing Physical Surgery:

Before these medications became widespread, severe mental health conditions were sometimes treated with physical psychosurgery (such as standard or transorbital lobotomies) or harsh shocks. Drugs offered a non-surgical, more predictable way to manage symptoms, though they carried their own intense sedative and neurological side effects.

Common Meanings and Contexts

Historical/Medical Metaphor:

Originally applied to the first generation of major tranquilizers and antipsychotics that suppressed acute mania, hallucinations, or severe agitation.

Critiques of Long-Term Medication:

In modern discussions, critics, patients, or advocacy groups sometimes use the term colloquially to describe the side effects of prolonged or high-dose psychiatric medications (such as antipsychotics, mood stabilizers, or heavy painkillers). These effects can include:

  • Emotional numbing or apathy
  • Cognitive dullness or brain fog
  • Chronic fatigue and physical sluggishness
  • Involuntary movements or tremors